With the two active components, sitagliptin and metformin, Janumet has a comprehensive mechanism of action that targets all three key defects of T2DM for improved glycemic control: diminished insulin ...
Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...
Takeda announced positive late-stage results for its new type 2 diabetes drug, fasiglifam (TAK-875), the first GPR40 agonist to reach late-stage development. Fasiglifam has the potential to be a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback